Welcome to our dedicated page for Arbutus Biopharma Corporation news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharma Corporation stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (cHBV). Utilizing its extensive expertise in virology, Arbutus focuses on developing a portfolio of drug candidates with multiple mechanisms of action aimed at curing Hepatitis B virus (HBV) disease. The company's lead RNA interference (RNAi) therapeutic, imdusiran (AB-729), targets HBV proteins to reduce viral antigens and reawaken the host's immune response. Imdusiran is currently undergoing multiple Phase 2a clinical trials, demonstrating promising results in reducing hepatitis B surface antigen (HBsAg) levels and achieving functional cures in a subset of patients.
Arbutus leverages its proprietary lipid nanoparticle (LNP) technology and expertise in RNAi therapeutics to develop innovative treatments. Beyond HBV, the company has a robust pipeline that includes AB-101, an oral PD-L1 inhibitor, currently in Phase 1a/1b trials. This compound aims to enable controlled checkpoint blockade while minimizing systemic safety issues.
Recent clinical data highlight the potential of Arbutus' combination therapies. In the IM-PROVE I trial, imdusiran combined with pegylated interferon alfa-2a (IFN) and nucleos(t)ide analogue (NA) therapy demonstrated sustained HBsAg loss in some patients, suggesting a path toward a functional cure. Another study, IM-PROVE II, showed that combining imdusiran with VTP-300, an immunotherapeutic, resulted in meaningful reductions in HBsAg levels and the discontinuation of NA therapy in a significant number of patients.
Financially, Arbutus maintains a strong position with a cash runway extending into the first quarter of 2026. They are actively involved in ongoing patent litigation to protect their LNP technology, seeking fair compensation for its use in mRNA COVID-19 vaccines by Moderna and Pfizer/BioNTech.
Arbutus continues to engage in strategic collaborations and partnerships to advance its mission of curing HBV and other chronic infectious diseases. For more detailed information, visit www.arbutusbio.com.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation focuses on the company's efforts to develop a cure for chronic hepatitis B virus (HBV) infections and therapies for coronaviruses, including COVID-19. Interested parties can access the webcast on Arbutus' website starting at 7:00 am (EST) on March 9, with an archived replay available afterward.
Assembly Biosciences and Arbutus Biopharma have initiated a Phase 2 clinical trial to evaluate the combination of Assembly's vebicorvir (VBR) and Arbutus’ AB-729 with standard NrtI therapy for chronic hepatitis B Virus (HBV) infection. The trial aims to enroll around 60 patients and assess the safety and antiviral activity of the treatments over 48 weeks. Both companies believe this multi-drug approach is essential for achieving a durable functional cure for HBV, addressing the significant unmet need in HBV therapies.
Arbutus Biopharma Corporation (Nasdaq: ABUS) will announce its fourth quarter and year-end 2020 financial results on March 4, 2021. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. The company focuses on developing a cure for chronic hepatitis B virus (HBV) and therapies for coronaviruses, including COVID-19. Live access to the conference call will be available via the company's investor website.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its 2021 objectives and financial update, focusing on its hepatitis B research and development pipeline. The lead asset, AB-729, shows promising Phase 1a/b clinical trial results, with plans for Phase 2a trials this year. Additionally, AB-836 is set to enter Phase 1a/1b trials. As of December 31, 2020, the company reported approximately $123.3 million in cash and anticipates a net cash burn of $70-75 million in 2021, extending its cash runway to mid-2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is participating in the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The virtual fireside chat will feature key executives, including President and CEO William Collier and Chief Scientific Officer Dr. Michael Sofia. The chat will be accessible via the company's website starting at 6:00 am EST on January 11, 2021. Arbutus focuses on developing treatments for chronic hepatitis B virus (HBV) and coronaviruses like COVID-19, with multiple drug candidates in progress.
Arbutus Biopharma (Nasdaq: ABUS) reported new clinical data from its Phase 1a/1b trial of AB-729, demonstrating significant safety and efficacy in treating chronic hepatitis B virus (HBV). The trial showed comparable declines in mean HBsAg levels with 60 mg doses administered every 4 weeks (–1.44 log10) and every 8 weeks (–1.37 log10, N=6). No serious adverse events were reported, reinforcing the drug's tolerability. The company aims to advance AB-729 into Phase 2a trials in 2021.
Arbutus Biopharma Corporation (Nasdaq: ABUS) released updated clinical data from its Phase 1a/1b trial of AB-729, an RNA interference therapeutic for chronic hepatitis B. The data showed significant declines in HBsAg with repeat 60 mg doses every 4 weeks, achieving a mean decline of -1.71 log10 IU/mL at week 20. A single 90 mg dose in HBV DNA positive subjects also resulted in meaningful reductions in HBsAg and HBV DNA. The company plans to advance AB-729 into Phase 2 combination studies, exploring less frequent dosing options. The product was reported to be safe and well tolerated.
Arbutus Biopharma Corporation (Nasdaq: ABUS) presented updated clinical data from its Phase 1a/1b trial of AB-729, a promising treatment for chronic hepatitis B infection. Key findings include a significant decline in HBsAg concentrations with repeat dosing of 60 mg every 4 weeks, showing further decline beyond week 12, with no plateau observed. AB-729 was generally safe and well tolerated, with expected decreases in HBV RNA and HBcrAg. A conference call is scheduled for November 16, 2020, to discuss these encouraging results further.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 12:35 pm EST. The company focuses on developing cures for chronic hepatitis B virus (HBV) infection and treatments for coronaviruses, including COVID-19. Attendees can access the live webcast through the company's website, with an archived replay available afterward. Arbutus continues to advance multiple drug candidates aimed at potentially curing chronic HBV.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its third quarter 2020 financial results, highlighting progress in its Phase 1a/1b clinical trial for AB-729, an RNAi therapeutic for chronic hepatitis B virus (HBV). AB-729 showed significant reductions in HBsAg with a favorable safety profile. The company had cash reserves of $118.3 million, sufficient to fund operations into mid-2022. Despite a net loss of $21.8 million for the quarter, this is an improvement from the previous year's loss. The clinical collaboration with Assembly Biosciences is set to evaluate AB-729 in combination therapies.
FAQ
What is the current stock price of Arbutus Biopharma Corporation (ABUS)?
What is the market cap of Arbutus Biopharma Corporation (ABUS)?
What is Arbutus Biopharma's primary focus?
What is imdusiran (AB-729)?
What are the key recent achievements of Arbutus Biopharma?
What is the status of Arbutus' financial condition?
What technologies does Arbutus leverage for its treatments?
What are the current projects Arbutus Biopharma is working on?
Has Arbutus formed any strategic partnerships?
What is the significance of Arbutus' patent litigation?
How successful have Arbutus' clinical trials been?
Where can more information about Arbutus Biopharma be found?
